Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M68.0Revenue $M24.5Net Margin (%)-280.8Altman Z-Score-3.2
Enterprise Value $M-57.9EPS $-0.5Operating Margin %-245.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score1.2Pre-tax Margin (%)-275.2Higher ROA y-yN
Price/Book2.110-y EBITDA Growth Rate %-27.7Quick Ratio6.9Cash flow > EarningsY
Price/Sales2.55-y EBITDA Growth Rate %-18.4Current Ratio7.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-312.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M146ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OREXSeth Klarman 2015-12-31 Add0.04%$1.57 - $3.32
($2.38)
$ 0.47-80%Add 176.17%2,268,399
OREXSeth Klarman 2015-09-30 Buy 0.03%$2.04 - $4.93
($3.44)
$ 0.47-86%New holding821,363
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
($3.76)
$ 0.47-88%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
($3.11)
$ 0.47-85%New holding500,000
OREXFirst Eagle Investment 2010-09-30 Sold Out -0.01%$3.9 - $6.77
($4.98)
$ 0.47-91%Sold Out0
OREXFirst Eagle Investment 2010-06-30 Add$4.05 - $7.04
($5.57)
$ 0.47-92%Add 74.07%470,000
OREXFirst Eagle Investment 2010-03-31 Add$5.9 - $7.66
($6.55)
$ 0.47-93%Add 22.73%270,000
OREXFirst Eagle Investment 2009-12-31 Add0.01%$6.44 - $9.39
($7.57)
$ 0.47-94%Add 83.33%220,000
OREXFirst Eagle Investment 2009-09-30 Buy 0.01%$5.2 - $10.34
($7.89)
$ 0.47-94%New holding120,000
OREXBill Gates 2009-06-30 Sold Out $1.89 - $5.21
($3.19)
$ 0.47-85%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Booth Mark DChief Commercial Officer 2015-02-26Sell50,000$5.68-91.73view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$6-92.17view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.83-91.94view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.58-91.58view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.57-91.56view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.47-89.49view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.78-90.17view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.69-89.98view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-93.97view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-93.77view

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Seth Klarman’s Largest New Buys and Adds Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 

More From Other Websites
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI... May 02 2016
8:31 am Orexigen Therapeutics announces South Korean approval of Contrave monotherapy for weight... May 02 2016
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI... May 02 2016
Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the... Apr 28 2016
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25 Apr 25 2016
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice... Apr 25 2016
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice... Apr 25 2016
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen Apr 21 2016
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on... Apr 20 2016
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on... Apr 20 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Apr 15 2016
ETF’s with exposure to Orexigen Therapeutics, Inc. : April 8, 2016 Apr 08 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events Apr 04 2016
ETF’s with exposure to Orexigen Therapeutics, Inc. : March 29, 2016 Mar 29 2016
Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 28 2016
Five Penny Stocks To Buy Based on Smart Money Sentiment Mar 26 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Mar 25 2016
Stocks To Watch: Market Update on Today's Stocks on the Move Mar 22 2016
The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron Mar 17 2016
Orexigen Buys U.S. Rights to Contrave, Inks Deal in the EU Mar 16 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)